{"id":78252,"date":"2026-03-09T00:05:20","date_gmt":"2026-03-09T00:05:20","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/"},"modified":"2026-03-09T00:05:20","modified_gmt":"2026-03-09T00:05:20","slug":"dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/","title":{"rendered":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"},"content":{"rendered":"<div>\n<p>NEW YORK and WALTHAM, Mass., March  08, 2026  (GLOBE NEWSWIRE) &#8212; Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET.<\/p>\n<p><strong>Investor Conference Call &amp; Webcast Information<\/strong><br \/>To access the live conference call by phone, please register\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6c2V9Y4DIcNQa2vRxbxaBHri201F11uMbDujtlS7V0i2Ypf9Y_ODb896hz1gs9_qkVG3VUSeAWf-KN0zPfvJWpmUd_U11UvBCfQ5WcAVJAVysyv8dvsQ3khLWVamcz1dMjKvZkVMVzeWLJPE9-CkR3bL0nhDCjgMftLshyqWMJk=\" rel=\"nofollow\" target=\"_blank\" title=\"here\">here<\/a>.\u00a0Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.\u00a0<\/p>\n<p>The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ot1U1wyHukWPwtjDwxt5Qisd2Nb7KZp9nSwiSR1CG8_0t6UKLpuwbyzvUEDhmnPO7bshcxZh2Ol4rw5o5U3Us7sWS6CZUCSrG_CKCGDWFUQVoormQ3VnVoovBV0FgUpZ\" rel=\"nofollow\" target=\"_blank\" title=\"live webcast\">live webcast<\/a> may be accessed via the Investors section of the Dianthus Therapeutics website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zWRlEbt58WF4bFR2auoi1x6-DoqxEFs19OuJ4yxvOyC18Yyh0ft4S_hEuv4T_uGcR3tQyCg2nTz9V2wdUks9Dh_YRDVigL8L5Nb7CgDFMwjbF106usEVZ5PxfPAc1krr\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/investor.dianthustx.com\/<\/a>. A replay of the webcast will be available following the call.<\/p>\n<p><strong>About Dianthus Therapeutics<\/strong><br \/>Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.<\/p>\n<p>To learn more, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PDbtoyGR_cOSYIEMJH_SyVGEvf3oYk0HO1nW2eBV2MvXDL6JO_ifZS8JG7r29LsVddJCZP4CCfX9xRxvaJRD1ok061qqIV5b5UzFUM0rhuY=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>www.dianthustx.com<\/u><\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KQM9NJoTkv-NzfreyUf9nRNCJOVQfjPn_n6Zmpx-3QphNhk0ritjcTKfTVBed-DxH7FxqVpHk282FIWiQb4G8svjQZSxHvApKIyspmLS93lr9Xho0prLTEz7Ye7NPi7SuavGyXn8-q3GmKYsfSRuQw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>LinkedIn<\/u><\/a>.\u00a0<\/p>\n<p><strong>Contact <\/strong><br \/>Jennifer Davis Ruff<br \/>Dianthus Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HMCgFSK_aQqUh0d9fvdvNd2h82PtntOAZeRI3kjECcxQYcWi6dcCGPZ02FgEmfgiOEAbsp_zntETGKJBQoVZhhyfoV9m7TAov1ACdvkPTt5UyT8fuaX0IsPcmYRlDW4_\" rel=\"nofollow\" target=\"_blank\" title=\"jdavisruff@dianthustx.com\">jdavisruff@dianthustx.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2FjNTFiZWYtNzBmMy00MTJiLThiYmUtZWUzNGNkNjRjYWYzLTEyNzE5MzktMjAyNi0wMy0wOC1lbg==\/tiny\/Dianthus-Therapeutics-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) &#8212; Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE [&#8230;]\n","protected":false},"author":1,"featured_media":78253,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-78252","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)\" \/>\n<meta property=\"og:description\" content=\"NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) &#8212; Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology compan\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T00:05:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml.globenewswire.com\/media\/Y2FjNTFiZWYtNzBmMy00MTJiLThiYmUtZWUzNGNkNjRjYWYzLTEyNzE5MzktMjAyNi0wMy0wOC1lbg==\/tiny\/Dianthus-Therapeutics-Inc-.png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)\",\"datePublished\":\"2026-03-09T00:05:20+00:00\",\"dateModified\":\"2026-03-09T00:05:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/\"},\"wordCount\":245,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/\",\"name\":\"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-03-09T00:05:20+00:00\",\"dateModified\":\"2026-03-09T00:05:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/","og_locale":"en_US","og_type":"article","og_title":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","og_description":"NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) &#8212; Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology compan","og_url":"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-03-09T00:05:20+00:00","og_image":[{"url":"https:\/\/ml.globenewswire.com\/media\/Y2FjNTFiZWYtNzBmMy00MTJiLThiYmUtZWUzNGNkNjRjYWYzLTEyNzE5MzktMjAyNi0wMy0wOC1lbg==\/tiny\/Dianthus-Therapeutics-Inc-.png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","datePublished":"2026-03-09T00:05:20+00:00","dateModified":"2026-03-09T00:05:20+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/"},"wordCount":245,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/","url":"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/","name":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-03-09T00:05:20+00:00","dateModified":"2026-03-09T00:05:20+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/78252","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=78252"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/78252\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/78253"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=78252"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=78252"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=78252"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}